Related references
Note: Only part of the references are listed.Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from southwest oncology group Randomized trials
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity
Haris Vikis et al.
CANCER RESEARCH (2007)
Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers
Tomoaki Tanaka et al.
CANCER SCIENCE (2007)
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
A. Sutani et al.
BRITISH JOURNAL OF CANCER (2006)
Pulmonary fibroblasts stimulate the proliferation of cell lines from human lung adenocarcinomas
Maria Cekanova et al.
ANTI-CANCER DRUGS (2006)
Clinical experience with gefitinib: An update
F Cappuzzo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers
N Ishikawa et al.
CANCER RESEARCH (2005)
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer
Y Tomizawa et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Autocrine, paracrine and juxtacrine signaling by EGFR ligands.
AB Singh et al.
CELLULAR SIGNALLING (2005)
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer
R Rosell et al.
LUNG CANCER (2005)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
Y Nagai et al.
CANCER RESEARCH (2005)
Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma
M Sonobe et al.
BRITISH JOURNAL OF CANCER (2005)
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
H Cortes-Funes et al.
ANNALS OF ONCOLOGY (2005)
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
TY Chou et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology
PA Jänne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
SW Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
T Mitsudomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Predictors of the response to gefitinib in refractory non-small cell lung cancer
KS Kim et al.
CLINICAL CANCER RESEARCH (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
SF Huang et al.
CLINICAL CANCER RESEARCH (2004)
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
S Kakiuchi et al.
HUMAN MOLECULAR GENETICS (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma
ETK Hsieh et al.
LUNG CANCER (2000)
Share Paper
